| Similar Articles |
|---|
 |
Bio-IT World
November 14, 2003
Jeff Augen |
Making Information-Based Medicine Work A confluence of scientific discovery and high-throughput technology has made information-based medicine possible -- and imperative.   |
Pharmaceutical Executive
June 1, 2005
Jan Malek |
When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require. |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
September 9, 2002
John P. Helfrich |
Data Management in High-Throughput Screening The high-throughput drug discovery field requires an optimal IT platform. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Pharmaceutical Executive
May 1, 2012 |
Super-Size Me Finding opportunities in the information explosion: big data, big challenges and big rewards. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
April 2007
Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics. |
Pharmaceutical Executive
July 1, 2005
Ellen H. Julian |
What Pharma Wants From IT Today Indications that compliance and productivity issues reign over information technology (IT) budgets at pharma companies were verified in the 2005 Pharmaceutical Executive/Life Science Insights Information Technology Survey of nearly 850 US pharma companies. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Bio-IT World
September 2005
Alan Louie |
Molecular Imaging: Smarter and Better The expanding opportunity for molecular imaging (MI) technology to significantly improve drug development has not gone unobserved. Several drug development companies have added imaging capabilities to their arsenal of drug development tools. |
The Motley Fool
September 28, 2006
Ralph Casale |
A Second Sell-Off at Molecular Devices The company, which makes equipment used in drug development, is struggling with lumpy revenues. |
The Motley Fool
January 30, 2007
Ralph Casale |
Molecular Devices Acquired Successful integration of companies like Molecular Devices and improvement of operating margins in the pharmaceutical contract research business unit should reward shareholders well. |
Bio-IT World
March 10, 2003
Michael Greeley |
Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand? |
D-Lib
Jan/Feb 2015
Assante et al. |
Science 2.0 Repositories: Time for a Change in Scholarly Communication In this work we introduce the notion of Science 2.0 Repository that aims at overcoming the methodological barriers by providing scientists with an integrated and innovative environment that supports "within" and "during" scholarly communication workflows. |
Bio-IT World
February 18, 2004 |
Strategic Insights High-throughput gene-expression analysis tools are moving rapidly into clinical labs, setting the stage for dramatic improvements in drug development. |
D-Lib
Sep/Oct 2012
Van de Sompel et al. |
A Perspective on Resource Synchronization The Web is highly dynamic, with resources continuously being created, updated, deleted, and moved. Web applications that leverage third party resources face the challenge of keeping in step with this rate of change. |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The NextBio Thing in Bioinformatics NextBio, which this fall officially introduced its platform after a year of beta testing by a handful of select organizations, aims to provide high-throughput information to researchers without them having to learn anything. |
Bio-IT World
April 15, 2003
Michael Greeley |
Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive? |
Bio-IT World
August 13, 2002
Judith S. Hurwitz |
Software for Life Sciences: A Few Requests At the core of the life science revolution is IT. There is a discrepancy, however, between the emerging technology requirements and the preparedness of the technology industry to meet the needs of this market. |
Bio-IT World
March 17, 2004 |
Signs of Spring Colin Hill, CEO of Gene Network Sciences, a predictive systems biology company, says the worst is behind the bio-IT industry. "The hype has dissipated, and companies are focused on delivering the results," he says. Hill's strategy includes developing additional products, which should generate near-term revenue. |
